Slide 1: Q3 Investor Presentation
Q3 Investor Presentation November 2025
Slide 2: Disclosures
Disclosures Forward-Looking Statements This presentation may contain "forward-looking statements," which include information concerning Celanese Corporation’s (the “Company”) plans objectives, goals, strategies, future revenues, cash flow, financial performance, synergies, capital expenditures, dele
Slide 3: Discussion Topics
Discussion Topics Earnings update Key actions and near- term imperatives 3
Slide 4: Q3 2025 Results
Q3 2025 Results Q3 2025 Results Q3 2025 Highlights Free Cash Flow* $375 M $1.34 ▪ Strong cash flow performance in Q3 ▪ On track to achieve FY2025 target range FREE CASH FLOW* ADJUSTED EPS* Engineered Materials (EM) ▪ Improved product mix driven by continued actions to improve pipeline quality throug
Slide 5: Q4 2025 Outlook
Q4 2025 Outlook Q4 2025 Outlook Q4 2025 Focus Areas ~ $0.85 - $1.00 ADJUSTED EPS* GUIDE ▪ Ongoing focus to identify and implement actions to improve earnings ▪ Western hemisphere seasonality ADJUSTED EBIT* GUIDANCE BY BUSINESS SEGMENT ▪ Demand environment across most $165 M – $175 M $165 M – $180 M
Slide 6: Celanese action plans within our leading business franchises are yielding results
Celanese action plans within our leading business franchises are yielding results Acetyl Chain → Maximize sales opportunities in downstream products → Drive productivity through low cost, U.S. based assets and strategic footprint actions → Leverage strength of the underlying operating model INCREASE
Slide 7: Strategic divestiture of Micromax® business
Strategic divestiture of Micromax® business “The Micromax divestiture further demonstrates our commitment to ~$500 million transaction price, generate shareholder value by subject to adjustment aggressively and prudently ✓ Transaction value based on proforma deleveraging our balance sheet. run-rate
Slide 8: Strong execution drives free cash flow delivery in 2025 despite weaker demand environment
Strong execution drives free cash flow* delivery in 2025 despite weaker demand environment $800 M ✓ Free cash flow* of $375 million in $700 M Q3 2025 ✓ 2025 YTD free cash flow* exceeds $498 M FY2024 ✓ Remain on track to achieve targeted $613 M $700 to $800 million FY2025 free cash flow1 generation A
Slide 9: Maintaining strong liquidity and aligning debt maturities with cash flow generation timing
Maintaining strong liquidity and aligning debt maturities with cash flow generation timing Consistent execution against Debt Maturity Profile1 deleveraging plans → Strong liquidity position with $1.4 B in cash and cash equivalents balance at quarter- end and $1.75 B undrawn revolving credit facility
Slide 10: Strong and sustainable free cash flow generation and divestitures drive deleveraging
Strong and sustainable free cash flow* generation and divestitures drive deleveraging Free Cash Flow* and Divestitures ($M) Net Debt ($B) Accelerating cash flow capabilities and strategic divestitures… … increasingly deployed to deleveraging ~$3.0 B Cash Generation ~$2.5 B+ of Baseline Cash Generati
Slide 11: Actions expected to deliver $120 M cost savings in 2025, with future incremental opportunities
Actions expected to deliver $120 M cost savings in 2025, with future incremental opportunities of $50 M - $100 M Cost Reduction Initiatives Cost Reduction Realization Targets by Year ($M) Near Term Cost $80 - $100 million Reductions of targeted annualized savings $10 - $80 primarily through headcoun
Slide 12: Lanaken site closure would help advance acetate tow business to next phase of value creation
Lanaken site closure would help advance acetate tow business to next phase of value creation 2023+ STRATEGIC 2025+ ACCELERATING LONG TERM ACCOMPLISHMENTS VALUE CREATION Strategic action in Acetate Tow: ✓ Segment integration ✓ Footprint optimization into the Acetyl Chain ✓ Enhanced productivity → Opt
Slide 13: Acetyl Chain: Highly Diverse Mix Across Product, End-Market, and Geographies
Acetyl Chain: Highly Diverse Mix Across Product, End-Market, and Geographies Acetyls chemistry supports everyday life Food & Building & Medical & Automotive & Packaging & Agriculture Construction Pharmaceutical Industrials Paper • Food additives • Paints & coatings • Medicine production • Safety gla
Slide 14: Acetyl Chain well-positioned to capture any recovery in building and construction
Acetyl Chain well-positioned to capture any recovery in building and construction through downstream applications → AC has evolved portfolio mix towards differentiated downstream applications → Grades developed by our technical teams enable customers to enhance critical properties in their applicati
Slide 15: EM uniquely positioned as a solutions provider across industries
EM uniquely positioned as a solutions provider across industries Leading Application High Impact Programs (HIPs) – high Broadest Polymer Portfolio performance, demanding projects that drive Development Capabilities Vectra® | Zenite® higher margins PERFORMANCE → 16 global technical centers POLYMERS F
Slide 16: Celanese Offers a Compelling Investment Opportunity
Celanese Offers a Compelling Investment Opportunity Our mission is to position Celanese Leadership driving Actions underway to Strong earnings as a top quartile change deliver near-term leverage as demand company for total earnings improvement recovers shareholder return by delivering earnings growt
Slide 17: Upcoming Investor Relations Events
Upcoming Investor Relations Events Nov 12 Morgan Stanley Conference, Boston Nov 13 Baird Conference, Chicago Nov 18 Fireside Chat with J.P. Morgan Dec 2 Citi Conference, New York Dec 3 Goldman Sachs Conference, New York 17